{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 114 of 128', \"Source data should as a general rule be recorded in the subject's medical record or other\", 'defined document normally used at the trial site. Source data not normally collected as a', 'routine part of the clinical practice at the site may be entered on a worksheet. Clinical', 'assessments/safety evaluations must be signed by medically qualified investigators.', \"If the worksheet does not become part of the subject's medical record, the following should as\", \"a minimum be added to the subject's medical record:\", 'Date(s) of conducting the informed consent process, including date of', 'provision of subject information.', 'A statement from the investigator to verify that each of the eligibility criteria', 'are met and documented.', 'Subject ID.', 'The fact that the subject is participating in a clinical trial in chronic hand', 'eczema including treatment with delgocitinib cream (1, 3, 8, or 20 mg/g) or', 'delgocitinib cream vehicle for 16 weeks of treatment plus 2 weeks of follow-', 'up.', 'Other relevant medical information.', 'Trial monitoring', 'During the course of the trial, CRA(s) will visit the trial site. These visits have the following', 'objectives: (i) to continually verify source data to confirm that data entered into the eCRF by', 'authorised site personnel are accurate, complete, and verifiable from source documents; (ii) to', 'confirm that the safety and rights of subjects are being protected; and (iii) to confirm that the', 'trial is being conducted in accordance with the currently approved protocol and any other trial', 'agreements, ICH-GCP, and all applicable regulatory requirements.', \"The monitoring visit intervals will depend on the trial site's recruitment rate and the\", 'compliance of the trial site with the protocol and ICH-GCP.', 'In order to perform their role effectively, CRAs and persons involved in quality assurance and', 'inspections will need direct access to source data, e.g. medical records, laboratory reports,', 'appointment books, etc. If the electronic medical record does not have a visible audit trail, the', 'investigator must provide the CRA with signed and dated printouts. In addition, relevant site', 'staff should be available for discussions at monitoring visits and between monitoring visits', '(e.g., by telephone).']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 115 of 128', 'Protocol compliance', 'Protocol deviations will be documented and notified to the investigator. Protocol deviations', 'will be assessed by LEO and major deviations described in the CTR.', 'Sponsor audits, IRB/IEC review, and regulatory agency inspections', 'The clinical trial will be subject to audits conducted by LEO or inspections from domestic or', 'foreign regulatory authorities or from IRBs/IECs. Audits and inspections may take place', 'during or after the trial. The investigator and the site staff as well as LEO staff have an', 'obligation to cooperate and assist in audits and inspections. This includes giving auditors and', 'inspectors direct access to all source documents and other documents at the trial site relevant', 'to the clinical trial. This includes permission to examine, verify and reproduce any records', 'and reports that are important to the evaluation of the trial.', 'If the trial site is contacted for an inspection by competent authorities, LEO must be notified', 'immediately.', 'Risk assessment', 'In this trial, the risks to critical trial processes and data have been evaluated.', 'Risk mitigation activities for endpoints include:', 'Ensuring consistent data with respect to assessments of efficacy (IGA and', 'HECSI), all assessors will receive training and whenever possible, the efficacy', 'assessments will be made by the same investigator at each visit for a given', 'subject to reduce inter-rater variability.', 'Ensuring subjects and investigational staff are well instructed and trained about', 'the use of the eDiary and the eDevice which will be used to collect the PROs', '(HESD, HEIS, PaGA, DLQI, EQ-5D-5L, QOLHEQ, WLQ, PGI-C).', 'Ensuring investigational staff are well instructed and trained in collecting', 'biomarker samples.', 'Ensuring administration of IMP is controlled and documented at the site. This', 'will be done by providing training and clear instructions to trial sites.', 'Ensuring that trial sites are well trained in safety procedures such as collection', 'and reporting of AEs.']\n\n###\n\n", "completion": "END"}